Potential cure for cancer could be ready in 2018

Image
IANS London
Last Updated : Nov 26 2017 | 7:30 PM IST

British scientists are in the process of developing an immune therapy based on blood cells from patients who have made "miracle" recoveries from cancer, a breakthrough that could lead to potential cure for millions.

Early results from tests conducted in laboratory not only signal better treatment for cancer but also a potential cure that could be ready to test on patients as early as next year, the express.co.uk reported.

The novel therapy involves neutrophil cells -- which form part of the body's first line of defence against foreign invaders.

Neutrophils kill cancer cells either directly by destroying them with chemicals or antibodies or indirectly by recruiting other immune system cells.

The researchers noted that they have found a way to extract the cancer-killing immune cells from donor blood and then multiply them by the million.

"We're not talking about simply managing cancer. We're looking at a curative therapy that you would receive once a week over five to six weeks," said Alex Blyth, Chief Executive of LIfT Biosciences -- a leading biotech company, that is now preparing for early trials on patients.

"Based on our laboratory and mouse model experiments, we would hope to see patients experiencing complete remission. Our ultimate aim is to create the world's first cell bank of immensely powerful cancer killing neutrophils," Blyth said.

A key advantage of neutrophil treatment is that a donor's cells can be given to anyone without fear of serious rejection, Blyth explained.

They live in the body for only five days and disappear before the recipient's immune system has got into gear.

"However, it's too early to say whether this research will be safe or effective in humans as they've only studied it in mice and cells. But we look forward to seeing future results," Anna Perman of Cancer Research UK was quoted by the express.co.uk as saying.

The trial, potentially starting in a year's time, would involve a small number of 20 to 40 patients.

--IANS

rt/umer/mr

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 26 2017 | 7:22 PM IST

Next Story